Dose-Dense AC Followed by Taxol With Herceptin Is Feasible

Article

A mature 70-patient report by Chau T. Dang, MD, et al, on cardiac safetyof dose-dense AC (doxorubicin and cyclophosphamide, 60/600 mg/m2 X4) followed by Taxol with Herceptinfor 52 weeks in HER2-positivepatients, has concluded that theregimen is feasible; 3 of 70 patients (4%) had cessation oftrastuzumab because of asymptomaticLVEF decline, about 6 monthsinto the treatment period.

A mature 70-patient report by ChauT. Dang, MD, et al, on cardiac safetyof dose-dense AC (doxorubicin andcyclophosphamide, 60/600 mg/m2 ×4) followed by Taxol with Herceptinfor 52 weeks in HER2-positivepatients, has concluded that theregimen is feasible (abstract 2101); 3of 70 patients (4%) had cessation oftrastuzumab because of asymptomaticLVEF decline, about 6 monthsinto the treatment period. No significantLVEF declines were observedafter dose-dense AC, as assessed bymonth 2 MUGA. One patient hadCHF at month 4 of treatment (baselineEF > 75% dropped to 45%). Investigatorsreported she is clinically wellon diuretic, ACE-inhibitor, and beta-blocker.

Related Videos
A panel of 5 experts on colorectal cancer
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
A panel of 5 experts on colorectal cancer
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Related Content